Description

Penumbra: STORM-PE Clinical Momentum & Physician Adoption—The Engine Behind Its Procedure Growth!

Penumbra, a company engaged in the innovative medical devices sector, has recently reported its financial performance for the third quarter of 2025. Total revenue for the quarter was $354.7 million, marking a year-over-year increase of 17.8% on a reported basis and 16.9% on a constant currency basis. This growth evidences Penumbra’s broad-based execution of its strategy and technological advancements, reflecting in significant progress across various business segments. U.S. sales were a driving force, constituting 77.5% of total revenues and showing a 21.5% year-over-year increase. Sales in thrombectomy equipment rose by 18.5% in the U.S., and the U.S. embolization and access business increased by 29.2%. Particularly strong results came from the company’s vascular thrombosis (VTE) segment, which saw a 34% year-over-year growth, aided by increased adoption of Penumbra’s proprietary CAVT technology. On the international front, revenues were $79.7 million, an increase of 6.